Information Provided By:
Fly News Breaks for September 19, 2018
NVCR
Sep 19, 2018 | 06:34 EDT
Wells Fargo analyst Larry Biegelsen raised his price target for Novocure to $58 ahead of the company's September 25 data presentation from the Phase 2 Stellar study of Optune for mesothelioma. Positive top-line data already disclosed by Novocure shows that Optune added to current standard of care improves survival in mesothelioma patients, Biegelsen tells investors in a research note. The analyst expects FDA approval in 2019 and keeps an Outperform rating on shares of Novocure.
News For NVCR From the Last 2 Days
There are no results for your query NVCR
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.